About Us

In Healthcare today, there is a tremendous need for well-validated biomarkers to objectively monitor red blood cell health. At Functional Fluidics our red blood cell function biomarker support these evolving needs.

Functional Fluidics is a high complexity CLIA-certified diagnostic lab. Our mission is to be the gold standard in red blood cell health starting with Sickle Cell Disease.

Our suite of assays is currently offered nationally to clinical providers, pharmaceutical, academic and biotech partners to support drug development and patient care.

Learn More

BiomarkerS

Functional Fluidics’ proprietary biomarkers are unique diagnostic platforms that assess red blood cell health by replicating the environment that red blood cells experience in our bodies. Our biomarker provide indices that determine health of the patient.

  • Adhesion Test: Measures the stickiness of RBCs within a whole blood sample under physiologic flow conditions and generates an adhesion index.
  • Mechanical Fragility Tests: Measures the ability of RBCs to survive physiologic stress and generates a mechanical fragility index (MFI).

Learn More

01
 
02
 

Our SERVICES

Functional Fluidics offers Contract Research and Send Out Testing Services across the US. Our partners include clinical providers, pharmaceutical, academic and biotech partners.

Our experienced scientific and technical team can assist in developing a successful research strategy to facilitate clinical studies/trials for our pharma partners. We can also work with Clinical Providers to determine what is the best testing process for their patients.

Our services have recently expanded to support the COVID-19 screening and testing needs within the U.S.

Learn More

001-1
 

Contract Research Services

Functional Fluidics provides Contract Research Services to pharmaceutical, BioTech and Academic Research companies. We are well-positioned to address the needs of clients with large-scale validation studies and to provide insights into the individual patient-level response critical for development of personalized medical applications.

Our suite of proprietary cell function assays can help validate assumptions or support clinical claims. If your organization is in the Pre-Clinical, Clinical or Post-Marketing research stage, you can benefit from our biomarkers and our expertise in defining Red Blood Cell Health.

Learn More

03
 
04
 

SEND OUT TESTING

Functional Fluidics offers Send Out Testing services to Clinical Providers. The test data is then used for patient monitoring as a clinical support tool.

Healthcare providers partner with Functional Fluidics to gain access to well-validated biomarkers to objectively assess the impact on red blood cell health, and ultimately their patients’ health.

Learn More

sevies4
 

SOLUTIONS FOR OUR PARTNERS

abc
 

Clinical Providers

Diagnosis and ongoing patient monitoring as a clinical tool

LEARN MORE
new04
 

Pharma

Contract Research Services leveraging our proprietary biomarker assays to support the advancement of red blood cell therapies.

LEARN MORE
new03
 

Insurance Payers

Improving patient lives while reducing the inefficiencies and costs across the healthcare network.

LEARN MORE
003-1
 

Investor Relations

As we continue our growth, we invite those interested in investing our expansion to engage with our team

LEARN MORE

Overview

This short video describes the origins of the company, based on research in the Hines Lab at Wayne State University. We have developed a suite of assays that address the need for better ways to assess blood function, starting with the experience of Dr. Hines as a Pediatric ICU Physician at Detroit Medical Center.

 

Why Choose Functional Fluidics?

  • New Project

    Proprietary Lab Tests

  • New Project(1)

    CLIA Certified Lab

  • New Project(5)

    Complex Tests Experience

  • New Project(2)

    Thought Leader Access

  • New Project(3)

    Specialized Staff

  • New Project(4)

    Strong Industry Relationships



Functional Fluidics Assays

Our suite of proprietary cell function assays can help validate assumptions or support clinical claims.

  • 10    
    Flow Adhesion of whole blood on VCAM-1 (FA-WB-VCAM)
    LEARN MORE
  • 11    
    Flow Adhesion of whole blood on P-Selectin (FA-WB-Psel)
    LEARN MORE
  • 12    
    Mechanical Fragility – Normoxia (MF)
    LEARN MORE
 

Evaluation of Longitudinal Pain Study in Sickle Cell Disease (ELIPSIS)

13
 
    

Sickle cell disease (SCD) is characterized by frequent and unpredictable vaso-occlusive episodes (VOEs) that produce severe pain, organ damage, and early death. Lack of reliable biomarkers to objectively define VOEs, hinders the development of clinically useful interventions to improve the care for these patients.

Functional Fluidics recently participated in a ground-breaking study involving sickle cell patients. This non-interventional, longitudinal, 6-month study aimed to develop tools to identify VOCs in SCD patients with or without health care utilization.

The study data suggest that Functional Fluidics FA-WB-VCAM assay may serve as a predictive biomarker for impending VEEs, and a monitoring biomarker to assess response to SCD-modifying therapies.

LEARN MORE
04-1    

Evaluation of Longitudinal Pain Study in Sickle Cell Disease (ELIPSIS) by Electronic Patient-Reported Outcomes, Actigraphy, and Biomarkers

Functional Fluidics Biomarker  Featured in ELIPSIS article in American Society of Hematology (ASH) Blood Magazine

Key Points

  • Feasibility of monitored out-of-hospital pain and patient-reported VOC days as endpoints for clinical trials in SCD is demonstrated.
  • ePROs, actigraphy, and laboratory biomarkers enable improved identification and assessment of in-hospital and out-of-hospital VOCs.
LEARN MORE
14    
 

Publications & Abstracts

Hemolytic Biomarkers Predict Adhesiveness of Sickle Blood Cells in a Clinical Adhesion Bioassay

The objective of this study was to identify hematologic lab values that contribute to cellular adhesion in our clinical adhesion bioassay.

Evaluation of Coagulation and Inflammatory Markers in Pediatric Patients on Extracorporeal Membrane Oxygenation (ECMO)

The aims of this study were to evaluate if novel laboratory tests could better predict patients at risk for bleeding and/or thrombosis compared to routine laboratory tests

Longitudinal Evaluation of a Standardized P-Selectin Flow Adhesion Bioassay: Potential Role for the Assessment and Prediction of Vaso-Occlusive Episodes in Sickle Cell Disease

Sevuparin blocks sickle blood cell adhesion and sickle-leucocyte rolling on immobilized L-selectin in a dosedependent manner

Impact of environment on Red Blood Cell ability to withstand mechanical stress

An approach to measuring RBC haemolysis and profiling RBC mechanical fragility

Low molecular weight heparin inhibits sickle erythrocyte adhesion to VCAM-1 through VLA-4 blockade in a standardized microfluidic flow adhesion assay

A Longitudinal Study to Identify and Assess Adhesion Indices during Vaso-Occlusive Crises in Adults and Adolescents with Sickle Cell Disease

PLEASE COMPLETE THE FORM BELOW FOR MORE INFORMATION: